Episode details
Available for over a year
The founders of German biotechnology company BioNTech were researching how to fight cancers using messenger RNA, "the unloved cousin of DNA", when covid-19 first appeared and they realised mRNA could be used to make a vaccine for the disease. Financial Times journalist Joe Miller has been following the company since just before the pandemic and tells Rebecca Kesby how they created the first covid-19 vaccine. Could mRNA help cure other diseases and improve vaccine access to low income countries? We ask Oksana Pyzik of the UCL School of Pharmacy. And how might the technology change the whole pharmaceutical industry? We hear from Dr Richard Torbett, CEO of the Association of the British Pharmaceutical Industry. Producer: Benjie Guy (Picture: a collection of mRNA covid vaccines. Credit: Getty Images.)
Programme Website